An interventional study of NeVa Stent Retriever in Acute Ischemic Stroke, sponsored by Vesalio. Recruiting at 3 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-31.
Sponsored by Vesalio · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Ischemic Stroke with a site in Argentina — 4 open to participants now, 5 under way, 2 of them phase 3. Ischemic Stroke · Argentina.
Among the 11 studies in Ischemic Stroke with a site in Argentina, this one is the only one that started in 2020, is one of 2 with no phase, and was the 7th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →4 of the 11 studies in Ischemic Stroke with a site in Argentina are open now. Recruiting first, the newest first:
Boehringer Ingelheim · Sites in Argentina, Australia, Bulgaria and 13 more countries
Ages 18+
University Hospital, Basel, Switzerland · Sites in Argentina, United States, Austria and 6 more countries
Ages 18+ · Women only
Medtronic Neurovascular Clinical Affairs · Sites in Argentina, Australia, Austria and 21 more countries
Ages 18+
A study can be open while its sites in Argentina have not opened yet or have stopped. Only those recruiting at a site in Argentina →
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 600 is above the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.
Median enrollment 4,790 across the 8 interventional studies, 1,000 across the 3 observational. Of the 6 that completed or were terminated, 4 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 11 have an industry lead sponsor. The 10 most frequent:
Vesalio is the lead sponsor of 9 studies on the registry; 2 are open to participants now.
Vesalio has 5 studies filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
2 of the studies in Ischemic Stroke with a site in Argentina that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07361302Phase 3Boehringer IngelheimA Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well | 2027-10-02 |
| NCT04562194VesalioNeVa ONE Registry Study | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies in Ischemic Stroke with a site in Argentina, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A prospective, open label study designed to assess the safety, performance and efficacy of thrombus removal in subjects presenting with acute ischemic stroke with the NeVa stent retrievers.
This is a prospective, open label, multi-center registry designed to assess the safety, performance and efficacy of the NeVa stent retriever in the treatment of large vessel occlusion strokes. Up to 600 subjects will be enrolled at up 30 sites.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Only subjects already treated with the NeVa thrombectomy devices can be considered for enrollment.
Imaging Inclusion Criteria:
The patient should have confirmed LVO and salvageable penumbra. Any automated software for determine the volume of viable tissue is acceptable. patient selection should follow the following guidelines:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NeVa Stent Retriever
Device: NeVa Stent Retriever
mechanical neurothrombectomy
First Pass Success Rate
The primary study endpoint is the first pass success rate with the NeVa device defined as eTICI score ≥ 2B \& eTICI ≥2C
Time frame: post-procedure day 0
Started Jul 2020 (actual). Primary completion is estimated for Dec 2026, 77 months after the start.
Of 80 industry-sponsored interventional studies with no phase under Ischemic Stroke, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 46. This study's planned 77 months is above that.
Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vesalio